Búsqueda - Portal Conocimiento Público CL

Article 2018

Structure-activity relationships based on 3D-QSAR CoMFA/CoMSIA and design of aryloxypropanol-amine agonists with selectivity for the human β3-adrenergic receptor and anti-obesity and anti-diabetic profiles

Autor: Lorca, M. Morales-Verdejo, C. Vásquez-Velásquez, D. Andrades-Lagos, J. Campanini-Salinas, J. Soto-Delgado, J. Recabarren-Gajardo, G. Mella, J.

The wide tissue distribution of the adrenergic β3 receptor makes it a potential target for the treatment of multiple pathologies such as diabetes, obesity, depression, overactive bladder (OAB), and cancer. Currently, there is only one drug on the market, mirabegron, approved for the treatment of ...

Enlace original: http://repositorio.unab.cl/xmlui/handle/ria/8959

Repositorio Universidad Andrés Bello

3D-QSAR

Aryloxypropanolamines

CoMFA

Listar archivos Citar Enlace permanente

Lorca, M. , Morales-Verdejo, C. , Vásquez-Velásquez, D. , Andrades-Lagos, J. , Campanini-Salinas, J. , Soto-Delgado, J. , Recabarren-Gajardo, G. , Mella, J. , [Structure-activity relationships based on 3D-QSAR CoMFA/CoMSIA and design of aryloxypropanol-amine agonists with selectivity for the human β3-adrenergic receptor and anti-obesity and anti-diabetic profiles] , Structure-activity relationships based on 3D-QSAR CoMFA/CoMSIA and design of aryloxypropanol-amine agonists with selectivity for the human β3-adrenergic receptor and anti-obesity and anti-diabetic profiles

Article 2017-03

2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity

Autor: Apablaza, G. Montoya, L. Morales-Verdejo, C. Mellado, M. Cuellar, M. Lagos, C.F. Soto-Delgado, J. Chung, H. Pessoa-Mahana, C.D. Mella, J.

The beta(3) adrenergic receptor is raising as an important drug target for the treatment of pathologies such as diabetes, obesity, depression, and cardiac diseases among others. Several attempts to obtain selective and high affinity ligands have been made. Currently, Mirabegron is the only availa...

Enlace original: http://repositorio.unab.cl/xmlui/handle/ria/4255

Repositorio Universidad Andrés Bello

QSAR

CoMSIA

Beta-3 adrenergic receptor

Listar archivos Citar Enlace permanente

Apablaza, G. , Montoya, L. , Morales-Verdejo, C. , Mellado, M. , Cuellar, M. , Lagos, C.F. , Soto-Delgado, J. , Chung, H. , Pessoa-Mahana, C.D. , Mella, J. , [2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity] , 2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity

Descubre y comparte nuestro conocimiento público

Resultados de búsqueda

Structure-activity relationships based on 3D-QSAR CoMFA/CoMSIA and design of aryloxypropanol-amine agonists with selectivity for the human β3-adrenergic receptor and anti-obesity and anti-diabetic profiles

2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity

Descubre y comparte nuestro conocimiento público

Resultados de búsqueda

Structure-activity relationships based on 3D-QSAR CoMFA/CoMSIA and design of aryloxypropanol-amine agonists with selectivity for the human β3-adrenergic receptor and anti-obesity and anti-diabetic profiles

[Lorca_Structure-Activity_Relationships.pdf]

2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity

[Apablaza_2D_QSAR.pdf]